Frontiers in HIV Pathogenesis, Therapy and Eradication

HIV发病机制、治疗和根除的前沿

• 批准号: 8260640
• 负责人: James Wavell Aiken
• 金额: $ 2万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-01-09 至 2012-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8260640
• 关键词: AIDS/HIV problem; Academia; Acquired Immunodeficiency Syndrome; Address; Antiviral Therapy; Area; Arts; Biology; Biology of HIV Infection; British Columbia; Canada; Cells; Cellular biology; Cessation of life; Chronic Hepatitis; Collaborations; Communication; Communication Research; Drug Formulations; Drug resistance; Educational workshop; Environment; Exposure to; Fostering; Gene Expression; HIV; HIV-1; Highly Active Antiretroviral Therapy; Industry; International; Joints; Knowledge; Maintenance; Mentors; Methodology; Outcome; Pathogenesis; Patients; Pharmacology; Private Sector; Request for Applications; Research; Research Personnel; Science; Scientist; Study models; Training; Viral; Viral hepatitis; Virus; abstracting; clinical practice; drug development; experience; frontier; inhibitor/antagonist; interest; latent infection; meetings; novel; pandemic disease; resistant strain; symposium; virus host interaction

DESCRIPTION: This application requests support for a Keystone Symposia meeting entitled Frontiers in HIV Pathogenesis, Therapy and Eradication, organized by Alan N. Engelman, Eric O. Freed and John M. Coffin, which will be held in Whistler, British Columbia, Canada from March 26-31, 2012. AIDS is incurable because cells latently infected with HIV resist antiviral therapy. Topical to the discussion of HIV eradication is the biology behind latent infection as well as models for the study of latency and pharmacological approaches to stimulate proviral gene expression. The Keystone Symposia meeting on Frontiers in HIV Pathogenesis, Therapy and Eradication will create an environment for free exchange of ideas and cutting edge results from a range of scientists in academia and industry in the fields of HIV pathogenesis, pharmacology, and eradication. Joint plenary sessions with the concurrent meeting on Cell Biology of Virus Entry, Replication and Pathogenesis will highlight common topics of interest including mechanisms of virus entry and inhibition, and will significantly enhance opportunities for interdisciplinary interactions. Leaders from HIV replication and drug resistance fields will critically examine the state of antiviral therapy, novel inhibitors, and important virus-host interactions. Speakers selected from submitted abstracts will fill-out workshops on pharmacological approaches and the cell biology of HIV infection. PUBLIC HEALTH RELEVANCE: The 2012 Keystone Symposium on Frontiers in HIV Pathogenesis, Therapy and Eradication will address key issues related to the control of the global HIV/AIDS pandemic including potential eradication of persistent viral reservoir(s) from patients. Considering that UNAIDS estimated 1.8 million AIDS-related deaths in 2009, the meeting is both timely and highly significant. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Cell Biology of Virus Entry, Replication and Pathogenesis, which will share a keynote address and two plenary sessions with this meeting.

说明： 本申请请求支持由Alan N.Engelman、Eric O.Freed和John M.Coffin组织的题为《艾滋病毒发病、治疗和根除的前沿》的Keystone研讨会，该会议将于2012年3月26-31日在加拿大不列颠哥伦比亚省惠斯勒举行。艾滋病是无法治愈的，因为潜伏感染艾滋病毒的细胞抵抗抗病毒治疗。讨论根除艾滋病毒的主题是潜伏感染背后的生物学，以及研究潜伏期和刺激前病毒基因表达的药理学方法的模型。关于艾滋病毒发病、治疗和根除前沿的Keystone研讨会将为学术界和工业界在艾滋病毒发病机制、药理学和根除领域的一系列科学家自由交流思想和尖端成果创造一个环境。与病毒进入、复制和致病的细胞生物学会议同时举行的联合全体会议将突出共同感兴趣的主题，包括病毒进入和抑制的机制，并将显著增加跨学科互动的机会。来自艾滋病毒复制和抗药性领域的领导人将严格审查抗病毒治疗、新型抑制剂和重要的病毒-宿主相互作用的状态。从提交的摘要中选出的发言者将填写有关药理学方法和艾滋病毒感染的细胞生物学的研讨会。 公共卫生相关性： 2012年艾滋病毒发病、治疗和根除前沿的Keystone研讨会将讨论与控制全球艾滋病毒/艾滋病大流行有关的关键问题，包括可能从患者体内根除持久性病毒储存库(S)。考虑到艾滋病规划署估计2009年有180万人死于艾滋病，这次会议既及时又意义重大。同时召开的病毒进入、复制和致病的细胞生物学会议将大大增加跨学科互动的机会，该会议将与本次会议举行一次主旨演讲和两次全体会议。